Novartis Partners with BasgenBio for AI-Powered Clinical Trial Simulation in Breast Cancer Research
Key Insights
BasgenBio (search) secures a 1 billion won ($684,090) deal with Novartis to implement AI-driven digital twin technology for predicting side effects in breast cancer (search) patients.
The Korean biotech company is simultaneously finalizing a larger licensing deal worth up to 100 billion won ($68.4 million) for an AI-discovered hair loss drug candidate.
BasgenBio (search)'s proprietary DeepCT platform leverages a 770,000-patient database and multi-omics integration to validate drug targets and predict trial outcomes before human testing begins.
BasgenBio (search), a Korean biotech company, is set to become Novartis' first AI-powered clinical trial simulation partner through a groundbreaking collaboration worth 1 billion won ($684,090). The partnership aims to revolutionize how pharmaceutical companies predict and manage drug side effects before human trials begin.
AI-Driven Approach to Clinical Trial Risk Assessment
The collaboration focuses specifically on predicting cholesterol-related complications in breast cancer (search) patients receiving Novartis treatment. BasgenBio (search)'s AI platform will analyze patient data to identify those at risk of developing these side effects, addressing a growing concern for the Swiss pharmaceutical giant.
"Pharma companies sink billions into trials and waste a decade chasing dead ends," explains BasgenBio (search) CEO Kim Ho. "AI-driven simulations can bring clarity before a single patient is ever dosed."
The company's proprietary DeepCT platform utilizes a unique database of 770,000 patients through an exclusive partnership with Yonsei University Health System. This repository includes comprehensive data on 14,000 cancer cases, 24,000 chronic disease cases, and 2,000 rare disease cases.
Multi-Omics Integration: A Novel Approach to Target Validation
Unlike traditional genomics-focused approaches, BasgenBio (search)'s platform integrates genomic, transcriptomic, and proteomic data to create what CEO Kim describes as "a living system" that captures complete disease development patterns. This comprehensive approach addresses a critical industry challenge: the lack of validated drug targets despite extensive genomic data collection.
"A drug is only as good as its target, and picking the wrong one can cost billions," Kim emphasizes, highlighting the limitation of purely genomic approaches used by companies like 23andMe, which lack the crucial context of medical records and biological data.
Expanding Portfolio and Commercial Progress
While advancing its AI simulation capabilities, BasgenBio (search) is simultaneously pursuing significant licensing opportunities. The company is finalizing a deal worth up to 100 billion won ($68.4 million), including a 5 billion won contract for an AI-discovered hair loss treatment. These compounds have reportedly shown promising results in cell-based experiments, outperforming existing treatments.
The company's financial trajectory shows steady improvement, with revenue growing from 480 million won in 2023 to 1.1 billion won in 2024. BasgenBio (search) projects reaching 10 billion won in revenue by 2025 and aims for 30 billion won by 2026, with plans for an IPO in late 2026.
Future Impact on Drug Development
The success of BasgenBio (search)'s model could transform pharmaceutical research and development. The company plans to charge 10% of projected trial costs for predictive insights, positioning itself as a crucial intermediary between experimental drugs and clinical outcomes. This approach could significantly reduce the industry's high failure rates and associated costs, such as AbbVie (search)'s recent $3.5 billion loss following the failure of emraclidine in Phase 2 trials.